142 related articles for article (PubMed ID: 33426919)
1. Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trial.
Wages NA; Reed DR; Keng MK; Conaway MR; Petroni GR
Clin Trials; 2021 Jun; 18(3):314-323. PubMed ID: 33426919
[TBL] [Abstract][Full Text] [Related]
2. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
Wages NA; Conaway MR
Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
[TBL] [Abstract][Full Text] [Related]
3. Concurrent dose-finding of a novel cancer drug with and without a second agent.
Wages NA; Saleh RR; Braun TM
J Clin Transl Sci; 2023; 7(1):e126. PubMed ID: 37313388
[TBL] [Abstract][Full Text] [Related]
4. Keyboard design for phase I drug-combination trials.
Pan H; Lin R; Zhou Y; Yuan Y
Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
[TBL] [Abstract][Full Text] [Related]
5. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
Wages NA; Fadul CE
Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
[TBL] [Abstract][Full Text] [Related]
6. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Thall PF; Cook JD; Estey EH
J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
[TBL] [Abstract][Full Text] [Related]
7. A two-dimensional biased coin design for dual-agent dose-finding trials.
Sun Z; Braun TM
Clin Trials; 2015 Dec; 12(6):596-607. PubMed ID: 26163309
[TBL] [Abstract][Full Text] [Related]
8. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
9. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Zang Y; Lee JJ
Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
[TBL] [Abstract][Full Text] [Related]
10. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
11. On the coherence of model-based dose-finding designs for drug combination trials.
Park Y; Liu S
PLoS One; 2020; 15(11):e0242561. PubMed ID: 33253260
[TBL] [Abstract][Full Text] [Related]
12. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
Pan H; Cheng C; Yuan Y
Pharm Stat; 2020 Sep; 19(5):561-582. PubMed ID: 32248647
[TBL] [Abstract][Full Text] [Related]
13. Isotonic design for phase I cancer clinical trials with late-onset toxicities.
Wages NA; Braun TM; Conaway MR
J Biopharm Stat; 2023 May; 33(3):357-370. PubMed ID: 36606874
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II adaptive design for drug combination oncology trials.
Wages NA; Conaway MR
Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations.
Jiménez JL; Kim S; Tighiouart M
Biom J; 2020 Sep; 62(5):1300-1314. PubMed ID: 32150296
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
17. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
Zhang L; Yuan Y
Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian response-adaptive dose-finding and comparative effectiveness trial.
Heath A; Yaskina M; Pechlivanoglou P; Rios D; Offringa M; Klassen TP; Poonai N; Pullenayegum E
Clin Trials; 2021 Feb; 18(1):61-70. PubMed ID: 33231105
[TBL] [Abstract][Full Text] [Related]
19. How to design a dose-finding study on combined agents: Choice of design and development of R functions.
Ezzalfani M
PLoS One; 2019; 14(11):e0224940. PubMed ID: 31710632
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding design for multi-drug combinations.
Wages NA; Conaway MR; O'Quigley J
Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
